Related Experiment Video
Updated: May 17, 2026
10:29
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor.
Mamta Sharma1, Louis D Saravolatz
1Division of Infectious Disease, Department of Medicine, St John Hospital & Medical Center, Detroit, MI, USA. mamta.sharma@stjohn.org
The Journal of Antimicrobial Chemotherapy
|October 27, 2012
Summary
Rilpivirine offers improved tolerability over efavirenz for HIV-1 treatment. However, drug interactions and specific mutations can reduce its effectiveness, impacting future non-nucleoside reverse transcriptase inhibitor options.
Area of Science:
- Pharmacology
- Infectious Diseases
- Virology
Background:
- Rilpivirine is an approved non-nucleoside reverse transcriptase inhibitor (NNRTI) for HIV-1 treatment-naive adults.
- It is administered orally as a 25 mg tablet once daily with a meal.
- Rilpivirine requires careful consideration due to potential drug interactions and resistance development.
Purpose of the Study:
- To review the efficacy, tolerability, and resistance profile of rilpivirine in HIV-1 management.
- To highlight key drug-drug interactions and contraindications for rilpivirine use.
- To identify specific NNRTI mutations associated with reduced rilpivirine susceptibility.
Main Methods:
- Review of clinical trial data comparing rilpivirine to efavirenz.
- Analysis of drug interaction profiles based on metabolic pathways (CYP450 3A4) and gastric pH.
- Examination of genotypic resistance data associated with rilpivirine treatment failure.
Main Results:
- Rilpivirine demonstrated better tolerability than efavirenz, with fewer CNS effects, rashes, and lipid abnormalities.
- Higher baseline viral loads and lower CD4 counts were associated with increased rates of virological failure.
- Seventeen specific NNRTI mutations were identified as conferring decreased susceptibility to rilpivirine.
Conclusions:
- Rilpivirine is a well-tolerated NNRTI option for specific HIV-1 patient populations.
- Awareness of drug interactions and potential for resistance is crucial for optimizing rilpivirine therapy.
- Development of rilpivirine resistance may limit future NNRTI treatment options.
Related Concept Videos
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
02:33Retroviruses
Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
01:29Viruses with RNA Genomes
RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
03:08LTR Retrotransposons
LTR retrotransposons are class I transposable elements with long terminal repeats flanking an internal coding region. These elements are less abundant in mammals compared to other class I transposable elements. About 8 percent of human genomic DNA comprises LTR retrotransposons. Some of the common examples of LTR retrotransposons are Ty elements in yeast and Copia elements in Drosophila.
The internal coding region of LTR retrotransposons and their mechanism of transposition closely resembles a...
The internal coding region of LTR retrotransposons and their mechanism of transposition closely resembles a...
01:29Subviral Agents
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...